Estrogen-related receptor ERRβ and ERRγ agonist / Selective agonist at estrogen-related receptors ERR and ERR with minimal activity at ERRα, ERα and ER at concentrations up to 30 μM.1 Displays antiproliferative activity in prostate cancer cells.2 Promotes hormone production and cell fusion in cytotrophoblasts.3 In breast cancer cells DY131 arrests cells in G2/M and causes mitotic spindle defects.4 Inhibits osteoclastogenesis and protects against inflammatory bone loss induced by LPS in vivo.5
Biochemicals & reagents
95167-41-2
GSK-9089
1) Yu and Forman (2005), Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma; Bioorg. Med. Chem. Lett., 15 1311 2) Yu et al. (2008), Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo groeth of prostate cancer cells via p21 (WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer; Oncogene, 27 3313 3) Poidatz et al. (2015), Trophoblast syncytialisation necessitates mitochondrial function through estrogen-related receptor-?; Mol. Hum. Reprod., 21 206 4) Heckler et al. (2016), Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRß2) splice variant in breast cancer; Oncotarget, 7 47201 5) Kim et al. (2019), Estrogen-related receptor ? negatively regulates osteoclastogenesis and protects against inflammatory bone loss; J. Cell Physiol., 234 1659
-20°C
TARGET: Transcription factor -- PATHWAY: Cell cycle; Estrogen; Transcription; MAPK; Apoptosis inducer; Transcription -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer